Clinical trial
Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer
NCT00303108 · US Oncology Research, Industry · Completed
Key facts
| NCT number | NCT00303108 |
|---|---|
| Title | Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer |
| Official title | Phase II Study of Doxil and Carboplatin, Plus Herceptin in HER2+ Patients, in Metastatic Breast Cancer |
| Lead sponsor | US Oncology Research, Industry |
| Collaborators | Ortho Biotech, Inc. Industry Tibotec Pharmaceutical Limited |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | Pegylated liposomal doxorubicin, Carboplatin, trastuzumab |
| Enrollment | 136 |
| Start date | Dec 1, 2005 |
| Primary completion | Mar 1, 2010 |
| Completion | Jun 1, 2011 |
| First posted | Mar 15, 2006 |
| Last update posted | Nov 3, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: